SCHEMBL5756525

SCHEMBL5756525

CS(=O)(=O)c1ccc(CBr)cc1Br.CS(=O)(=O)c1ccc(CO)cc1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
CA5B Q9Y2D0 1/20 0.37
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PTGS2 P35354 1/20 0.35
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5792762 0.93 CA2 (0.41) CA2CA12CA1CA4CA6
SCHEMBL1017626 0.92 L3MBTL1 (0.40) CYP1A2CYP2D6CYP2C9CYP2C19NPSR1
SCHEMBL5757459 0.83 ADRA1D (0.43) CA2CA12CA1CA4CA6
SCHEMBL28758223 0.78 KMT2A (0.35) CA2L3MBTL1PTGS2PIK3CDPIK3CA
SCHEMBL842705 0.78 L3MBTL1 (0.53) CA2CA12CA1CA4CA6
SCHEMBL1017170 0.78 EDNRB (0.37) CA2CA1CA4CA6L3MBTL1
SCHEMBL29087796 0.78 CA2 (0.52) CA2CA12CA1CA4CA6
SCHEMBL5755638 0.76 CA2 (0.42) CA2CA12CA1CA4CA6
SCHEMBL5756302 0.75 L3MBTL1 (0.55) CA2CA1L3MBTL1ALDH1A1LMNA
SCHEMBL3238980 0.75 GSTO1 (0.43) CA2CA12CA1CA4CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 CA2 2787/4885CA12 4849/4885CA1 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.